Loading
Metabolism, Diabetes, and Cancer / Diabetes Treatment and Management · Review
Clinical and Experimental Medicine · September 3, 2026
Well-designed and adequately powered for the question it asks.
This meta-analysis of 48 RCTs found no statistically significant association between SGLT2 inhibitor use and gastrointestinal neoplasm risk in type 2 diabetes across overall and site-specific analyses. The authors characterize the evidence as reassuring but not definitive, owing to limited follow-up duration in many trials and outcome ascertainment via adverse event reporting rather than centralized cancer adjudication.
Systematic review and meta-analysis of randomized controlled trials. Randomized controlled trials in patients with type 2 diabetes mellitus comparing SGLT2 inhibitors with placebo or active comparators; eligible trials reported gastrointestinal neoplasm outcomes.. Intervention: SGLT2 inhibitor therapy (agents included canagliflozin, dapagliflozin, empagliflozin and others). Compared with: Placebo or active comparator agents. n = 48,765. Multinational; database search without geographic restriction specified..
Overall GI neoplasm risk OR = 1.10 (95% CI 0.84–1.44, p = 0.46) across 48 RCTs with n = 48,765 No significant site-specific associations: esophageal OR = 1.12 (0.37–3.45), gastric OR = 1.20 (0.65–2.23), hepatic OR = 0.62 (0.31–1.22), pancreatic OR = 0.91 (0.51–1.64), colonic OR = 1.28 (0.78–2.08), colorectal OR = 0.76 (0.27–2.17), rectal OR = 0.98 (0.49–1.97) Subgroup analyses by specific agents (canagliflozin, dapagliflozin, empagliflozin), age, BMI, HbA1c, duration, and dose all non-significant (all p > 0.05)
Primary outcome measured as adverse events in trial publications or registries, not centrally adjudicated cancer endpoints with standardized definitions. Low event counts for site-specific neoplasms; wide confidence intervals for several site-specific analyses include both protective and harmful estimates.
Clinicians should interpret the available RCT evidence as reassuring regarding short-term gastrointestinal neoplasm risk with SGLT2 inhibitors, though long-term oncologic safety remains incompletely characterized due to limited follow-up duration and event counts in trial populations. The findings do not preclude longer-term or observational assessment in clinical practice.
A rigorous meta-analysis of 48 RCTs with 48,765 participants showing no significant association between SGLT2 inhibitors and gastrointestinal neoplasm risk, with consistent null findings across multiple site-specific and subgroup analyses, though long-term safety remains incompletely characterized.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should interpret the available RCT evidence as reassuring regarding short-term gastrointestinal neoplasm risk with SGLT2 inhibitors, though long-term oncologic safety remains incompletely characterized due to limited follow-up duration and event counts in trial populations. The findings do not preclude longer-term or observational assessment in clinical practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
The potential carcinogenic effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors in patients with type 2 diabetes mellitus (T2DM) remain controversial, particularly regarding site-specific gastrointestinal (GI) neoplasms. This systematic review and meta-analysis aimed to determine the relationship between SGLT2 inhibitors and the risk of GI neoplasms in patients with T2DM. We searched PubMed, EMBASE, Cochrane CENTRAL, Scopus, and Web of Science through March 17, 2025, for RCTs in T2DM comparing SGLT2 inhibitors with placebo or active comparators. Two reviewers independently screened studies, extracted data, and assessed the risk of bias. The primary outcome was GI neoplasms reported in publications, supplementary materials, or trial registries, usually as adverse events rather than centrally adjudicated cancer endpoints. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated in Stata 17.0. In 48 RCTs (n = 48,765), SGLT2 inhibitor therapy was not associated with overall GI neoplasm risk (OR = 1.10, 95% CI: 0.84-1.44; p = 0.46; I² = 0%). Site-specific analyses showed no statistically significant association for esophageal (OR = 1.12, 95% CI 0.37-3.45), gastric (1.20, 0.65-2.23), hepatic (0.62, 0.31-1.22), pancreatic (0.91, 0.51-1.64), colonic (1.28, 0.78-2.08), colorectal (0.76, 0.27-2.17), and rectal neoplasms (0.98, 0.49-1.97), with all p-values > 0.05. Subgroup analyses by agents (e.g., canagliflozin, dapagliflozin, empagliflozin), baseline age, body mass index (BMI), HbA1c, treatment duration, and dose were also non-significant (all p > 0.05). Approximately half of the trials had follow-up of one year or less, limiting our ability to evaluate long-term risk. Available RCT evidence does not show a clear increase in GI neoplasm risk with SGLT2 inhibitors in T2DM. However, limited follow-up, low event counts, and non-cancer-specific outcome ascertainment, the findings should be interpreted as reassuring but not definitive evidence of long-term oncologic safety.Systematic review registration: PROSPERO No. CRD42024619019.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.